Volatile anesthetics and liver injury: A clinical update or what every anesthesiologist should know

  • Jackie L. Martin


The use of any anesthetic agent must be based on specific knowledge of its benefits and risks, how it may produce toxicity and in which patients it may be most safely administered. Clearly, the perfect anesthetic agent does not yet exist and individual patient circumstances will continue to dictate the choice and use of inhaled anesthetics in clinical practice. Reports such as that by Tungea et al. remind us of the need for continued vigilance. As ongoing research attempts to uncover emerging toxicities, the clinician is challenged to balance new information with current clinical practices and choose the safest, most effective agents for each patient.


Halothane Sevoflurane Anesthetic Agent Enflurane Hepatic Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Les anesthésiques volatiles et l’atteinte hépatique: une mise à jour clinique ou ce que tout anesthésiologiste devrait savoir


L’usage de tout anesthésique doit reposer sur la connaissance spécifique de ses avantages et de ses risques, de la façon qu’il peut produire de la toxicité et des patients chez qui il peut être administré sans danger. Certes, l’anesthésique parfait n’existe pas encore et les particularités individuelles des patients guideront encore le choix et l’usage cliniques des anesthésiques par inhalation. Des articles comme celui de Tunget coll. rappellent la nécessité d’être toujours vigilant. Au moment où la recherche en cours tente de découvrir de nouvelles toxicités, le clinicien fait face au défi d’équilibrer les informations récentes et les habitudes cliniques courantes et de choisir l’anesthésique le plus sûr et le plus efficace pour chaque patient.


  1. 1.
    Tung D, Yoshida EM, Wang CS, Steinbrecher UP. Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anesth 2005; 52: 133–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84: 173–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoet P, Graf ML, Bourdi M, et al. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 1997; 350: 556–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris JW, Pohl LR, Martin JL, Anders MW. Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trichloroethane. Proc Natl Acad Sci USA 1991; 88: 1407–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Sadove MS, Kim SI. Hepatitis after use of two different fluorinated anesthetic agents. Anesth Analg 1974; 53: 336–40.CrossRefGoogle Scholar
  6. 6.
    Sigurdsson J, Hreidarsson AB, Thejodleifsson B. Enflurane hepatitis. A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985; 29: 495–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Martin JL, Kenna JG, Pohl LR. Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990; 70: 154–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Martin JL, Keegan MT, Vasdev GM, et al. Fatal hepatitis associated with isoflurane exposure and CYP2A6 autoantibodies. Anesthesiology 2001; 95: 551–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Cousins MJ, Plummer JL, Hall PD. Risk factors for halothane hepatitis. Aust N Z Surg 1989; 59: 5–14.CrossRefGoogle Scholar
  11. 11.
    Njoku DB, Greenberg RS, Bourdi M, et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002; 94: 243–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113: 580–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Luttropp HH, Thomasson R, Dahm S, Persson J, Wernfr O. Clinical experience with minimal xenon anesthesia. Acta Anaesthesiol Scand 1994; 38: 121–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Rossaint R, Reyle-Hahn M, Schulte Am Esch J, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003; 98: 6–13.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 2005

Authors and Affiliations

  1. 1.From the Department of Anesthesiology and Critical Care MedicineThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations